Vivimed Labs Intrinsic Value
Vivimed Labs (VIVIMEDLAB) median intrinsic value is ₹19.07 from 2 valuation models (range ₹15–₹19), vs current price ₹7.63 — +149.9% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit Vivimed Labs share price chart.
VIVIMEDLAB Valuation Methods Summary — DCF, Graham Number & P/E
Vivimed Labs intrinsic value across 2 models vs current price ₹7.63 — upside/downside and value range per method. Also explore VIVIMEDLAB price movement history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹15.26 | ₹13.73 - ₹16.79 | +100.0% | Revenue/Share: ₹49.41, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹19.07 | ₹15.26 - ₹22.88 | +149.9% | CF Growth: 5.0%, Discount: 15% |
VIVIMEDLAB Intrinsic Value vs Market Price — All Valuation Models
Vivimed Labs fair value range ₹15–₹19 vs current market price ₹7.63 across 2 valuation models. Browse VIVIMEDLAB annual financials for revenue, profit, balance sheet and cash flow data.
VIVIMEDLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Vivimed Labs median intrinsic value ₹19.07, current price ₹7.63 — Trading Below Calculated Value by 149.9%, margin of safety 60.0%.
What is the intrinsic value of VIVIMEDLAB?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Vivimed Labs (VIVIMEDLAB) is ₹19.07 (median value). With the current market price of ₹7.63, this represents a +149.9% variance from our estimated fair value.
The valuation range spans from ₹15.26 to ₹19.07, indicating ₹15.26 - ₹19.07.
Is VIVIMEDLAB undervalued or overvalued?
Based on our multi-method analysis, Vivimed Labs (VIVIMEDLAB) appears to be trading below calculated value by approximately 149.9%.
VIVIMEDLAB Financial Health — Key Ratios vs Industry Benchmarks
Vivimed Labs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.60 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 80.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.09x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VIVIMEDLAB Cash Flow Quality — Operating & Free Cash Flow
Vivimed Labs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-24 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹35 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹28 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹567 Cr | ₹567 Cr | Positive Free Cash Flow | 8/10 |